WO2002036562A2 - 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands - Google Patents
1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands Download PDFInfo
- Publication number
- WO2002036562A2 WO2002036562A2 PCT/US2001/045389 US0145389W WO0236562A2 WO 2002036562 A2 WO2002036562 A2 WO 2002036562A2 US 0145389 W US0145389 W US 0145389W WO 0236562 A2 WO0236562 A2 WO 0236562A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- piperazin
- sulfonyl
- alkyl
- indole
- formula
- Prior art date
Links
- 0 *[n]1c2cccc(N3CCNCC3)c2cc1 Chemical compound *[n]1c2cccc(N3CCNCC3)c2cc1 0.000 description 4
- HJKFMARMANEJDG-UHFFFAOYSA-N CSC1N=CCN1 Chemical compound CSC1N=CCN1 HJKFMARMANEJDG-UHFFFAOYSA-N 0.000 description 1
- JJGATASVZYYFPN-UHFFFAOYSA-N C[S](C)(c1ccccc1)(Cl)(=O)=O Chemical compound C[S](C)(c1ccccc1)(Cl)(=O)=O JJGATASVZYYFPN-UHFFFAOYSA-N 0.000 description 1
- KYJSJWZAMIFEAA-UHFFFAOYSA-N O=S(c1ccccc1)([n](c1ccc2)ncc1c2N1CCC(C2)C2(Cc2ccccc2)CCC1)=O Chemical compound O=S(c1ccccc1)([n](c1ccc2)ncc1c2N1CCC(C2)C2(Cc2ccccc2)CCC1)=O KYJSJWZAMIFEAA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0303756A HUP0303756A3 (en) | 2000-11-02 | 2001-10-31 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands and process for their preparation and pharmaceutical compositions containing them |
AU2005102A AU2005102A (en) | 2000-11-02 | 2001-10-31 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
KR1020037006000A KR100822655B1 (en) | 2000-11-02 | 2001-10-31 | 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands, a process for preparing the same and a pharmaceutical composition comprising the same |
EA200300528A EA006205B1 (en) | 2000-11-02 | 2001-10-31 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
IL15544301A IL155443A0 (en) | 2000-11-02 | 2001-10-31 | 1- aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
BRPI0115102-9B1A BR0115102B1 (en) | 2000-11-02 | 2001-10-31 | 1-Aryl or 1-alkylsulfonylheterocyclylbenzazoles compounds and composition comprising them |
MXPA03003800A MXPA03003800A (en) | 2000-11-02 | 2001-10-31 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands. |
CA2426031A CA2426031C (en) | 2000-11-02 | 2001-10-31 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
EP01992697A EP1343756A2 (en) | 2000-11-02 | 2001-10-31 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
NZ525592A NZ525592A (en) | 2000-11-02 | 2001-10-31 | 1-Aryl- or 1-alkylsufonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
JP2002539322A JP4184077B2 (en) | 2000-11-02 | 2001-10-31 | 1-aryl or 1-alkylsulfonyl-heterocyclylbenzazole as 5-hydroxytryptamine-6 ligand |
AU2002220051A AU2002220051B2 (en) | 2000-11-02 | 2001-10-31 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
IL155443A IL155443A (en) | 2000-11-02 | 2003-04-15 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles, process for their preparation and pharmaceutical compositions for treatment of cns disorders affected by 5-ht6 receptors |
NO20031977A NO326610B1 (en) | 2000-11-02 | 2003-04-30 | 1-aryl or 1-alkylsulfonyl-heterocyclyl benzazoles, their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24511800P | 2000-11-02 | 2000-11-02 | |
US60/245,118 | 2000-11-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002036562A2 true WO2002036562A2 (en) | 2002-05-10 |
WO2002036562A3 WO2002036562A3 (en) | 2003-01-23 |
Family
ID=22925357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/045389 WO2002036562A2 (en) | 2000-11-02 | 2001-10-31 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
Country Status (19)
Country | Link |
---|---|
US (3) | US20020115670A1 (en) |
EP (2) | EP2298738B1 (en) |
JP (1) | JP4184077B2 (en) |
KR (1) | KR100822655B1 (en) |
CN (1) | CN1222511C (en) |
AR (1) | AR034270A1 (en) |
AU (2) | AU2002220051B2 (en) |
BR (1) | BR0115102B1 (en) |
CA (1) | CA2426031C (en) |
EA (1) | EA006205B1 (en) |
HU (1) | HUP0303756A3 (en) |
IL (2) | IL155443A0 (en) |
MX (1) | MXPA03003800A (en) |
NO (1) | NO326610B1 (en) |
NZ (1) | NZ525592A (en) |
PL (1) | PL213134B1 (en) |
TW (1) | TWI282787B (en) |
WO (1) | WO2002036562A2 (en) |
ZA (1) | ZA200304188B (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002102774A1 (en) * | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
WO2003068771A1 (en) * | 2002-02-18 | 2003-08-21 | Glaxo Group Limited | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors |
WO2003104193A1 (en) * | 2002-06-05 | 2003-12-18 | F. Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
WO2004026831A1 (en) * | 2002-09-17 | 2004-04-01 | F. Hoffmann-La Roche Ag | 2,4-substituted indoles and their use as 5-ht6 modulators |
EP1408976A1 (en) * | 2001-07-20 | 2004-04-21 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
WO2005037834A1 (en) * | 2003-10-20 | 2005-04-28 | Biovitrum Ab | NOVEL TETRAYDROSPIRO{PIPERIDINE-2,7’ -PYRROLO[3,2-b]PYRIDINE DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS |
US7087750B2 (en) | 2000-10-20 | 2006-08-08 | Biovitrum Ab | Compounds, their use and preparation |
JP2007509898A (en) | 2003-11-03 | 2007-04-19 | プロビオドルグ エージー | Useful combinations for the treatment of neurological disorders |
US7381728B2 (en) | 2004-07-28 | 2008-06-03 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
WO2008084492A1 (en) * | 2007-01-08 | 2008-07-17 | Suven Life Sciences Limited | 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands |
CN100422171C (en) * | 2003-02-14 | 2008-10-01 | 惠氏公司 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
US7452888B2 (en) | 2002-03-27 | 2008-11-18 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
US7696229B2 (en) | 2006-02-17 | 2010-04-13 | Memory Pharmaceuticals Corporation | Compounds having 5-HT6 receptor affinity |
US7713978B2 (en) | 2006-03-31 | 2010-05-11 | Nigel Paul King | Compounds |
WO2010056644A1 (en) * | 2008-11-11 | 2010-05-20 | Wyeth Llc | 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS |
US7750038B2 (en) | 2007-03-06 | 2010-07-06 | Wyeth Llc | Sulfonylated heterocycles useful for modulation of the progesterone receptor |
US7973069B2 (en) | 2004-07-14 | 2011-07-05 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US8003670B2 (en) | 2007-05-03 | 2011-08-23 | Suven Life Sciences Limited | Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands |
US8293738B2 (en) | 2010-05-12 | 2012-10-23 | Abbott Laboratories | Indazole inhibitors of kinase |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
WO2013001499A1 (en) | 2011-06-29 | 2013-01-03 | Adamed Sp. Z O.O. | Indoleamine derivatives for the treatment of central nervous system diseases |
US8404720B2 (en) | 2008-09-17 | 2013-03-26 | Suven Life Sciences Limited | Aryl sulfonamide amine compounds and their use as 5-HT6 ligands |
US8940716B2 (en) | 2010-05-06 | 2015-01-27 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as GPR119 modulators |
WO2015019365A1 (en) | 2013-08-07 | 2015-02-12 | Cadila Healthcare Limited | N-cyanomethylamides as inhibitors of janus kinase |
WO2016038160A1 (en) * | 2014-09-11 | 2016-03-17 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9663498B2 (en) | 2013-12-20 | 2017-05-30 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
US9745270B2 (en) | 2008-10-28 | 2017-08-29 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US9775829B2 (en) | 2003-07-22 | 2017-10-03 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
US9808455B2 (en) | 2007-12-12 | 2017-11-07 | Axovant Sciences Gmbh | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US10059691B2 (en) | 2008-04-02 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
WO2020002611A1 (en) | 2018-06-28 | 2020-01-02 | Phenex-Fxr Gmbh | Novel lxr modulators with bicyclic core moiety |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4187642B2 (en) * | 2001-06-07 | 2008-11-26 | エフ.ホフマン−ラ ロシュ アーゲー | Novel indole derivatives having 5-HT6 receptor affinity |
CN1321110C (en) * | 2001-06-15 | 2007-06-13 | 弗·哈夫曼-拉罗切有限公司 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity |
RU2429231C2 (en) * | 2005-08-15 | 2011-09-20 | Вайет | Derivatives of substituted 3-sulphonylindazole as 5-hydroxytryptamine-6 ligands |
PE20071143A1 (en) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | PHARMACEUTICAL COMPOSITION INCLUDING AN ACETYLCHOLINESTERASE INHIBITOR AND A 5-HYDROXITRIPTAMINE-6 ANTAGONIST |
WO2007117413A1 (en) * | 2006-04-05 | 2007-10-18 | Wyeth | Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands |
WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
WO2008084491A1 (en) * | 2007-01-08 | 2008-07-17 | Suven Life Sciences Limited | 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands |
CA2674087A1 (en) * | 2007-02-16 | 2008-08-21 | Memory Pharmaceuticals Corporation | 6' substituted compounds having 5-ht6 receptor affinity |
MX2010001576A (en) * | 2007-08-15 | 2010-09-14 | Memory Pharm Corp | 3' substituted compounds having 5-ht6 receptor affinity. |
US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
US8183237B2 (en) | 2009-04-30 | 2012-05-22 | Abbott Laboratories | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
CN103880750A (en) * | 2014-03-18 | 2014-06-25 | 上海皓元生物医药科技有限公司 | Method for preparing key intermediate of Tenelia |
CA2953004C (en) * | 2014-07-08 | 2023-02-21 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
WO2016071293A2 (en) * | 2014-11-03 | 2016-05-12 | Iomet Pharma Ltd | Pharmaceutical compound |
UY37412A (en) * | 2016-09-23 | 2018-04-30 | Novartis Ag | INDAZOL COMPOUNDS FOR USE IN INJURY OF TENDONS AND / OR LIGAMENTS |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2194984C (en) * | 1994-07-26 | 2002-07-02 | John Eugene Macor | 4-indole derivatives as serotonin agonists and antagonists |
US5849759A (en) * | 1995-12-08 | 1998-12-15 | Berlex Laboratories, Inc. | Naphthyl-substituted benzimidazole derivatives as anti-coagulants |
GB9716656D0 (en) * | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
DK0930302T3 (en) * | 1998-01-16 | 2003-07-21 | Hoffmann La Roche | Benzosulfone derivatives |
US6251893B1 (en) * | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
SE0002754D0 (en) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
EP1326830A1 (en) * | 2000-10-20 | 2003-07-16 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
-
2001
- 2001-10-31 EA EA200300528A patent/EA006205B1/en not_active IP Right Cessation
- 2001-10-31 AU AU2002220051A patent/AU2002220051B2/en not_active Ceased
- 2001-10-31 PL PL362138A patent/PL213134B1/en unknown
- 2001-10-31 AU AU2005102A patent/AU2005102A/en active Pending
- 2001-10-31 WO PCT/US2001/045389 patent/WO2002036562A2/en active IP Right Grant
- 2001-10-31 IL IL15544301A patent/IL155443A0/en unknown
- 2001-10-31 CA CA2426031A patent/CA2426031C/en not_active Expired - Fee Related
- 2001-10-31 BR BRPI0115102-9B1A patent/BR0115102B1/en not_active IP Right Cessation
- 2001-10-31 EP EP10177536A patent/EP2298738B1/en not_active Expired - Lifetime
- 2001-10-31 HU HU0303756A patent/HUP0303756A3/en unknown
- 2001-10-31 EP EP01992697A patent/EP1343756A2/en not_active Withdrawn
- 2001-10-31 JP JP2002539322A patent/JP4184077B2/en not_active Expired - Fee Related
- 2001-10-31 CN CNB018216587A patent/CN1222511C/en not_active Expired - Fee Related
- 2001-10-31 MX MXPA03003800A patent/MXPA03003800A/en active IP Right Grant
- 2001-10-31 KR KR1020037006000A patent/KR100822655B1/en not_active IP Right Cessation
- 2001-10-31 NZ NZ525592A patent/NZ525592A/en not_active IP Right Cessation
- 2001-11-01 US US10/003,015 patent/US20020115670A1/en not_active Abandoned
- 2001-11-01 TW TW1-ARYL-ORA patent/TWI282787B/en not_active IP Right Cessation
- 2001-11-01 AR ARP010105112A patent/AR034270A1/en unknown
-
2003
- 2003-04-15 IL IL155443A patent/IL155443A/en not_active IP Right Cessation
- 2003-04-30 NO NO20031977A patent/NO326610B1/en not_active IP Right Cessation
- 2003-05-29 ZA ZA200304188A patent/ZA200304188B/en unknown
- 2003-12-04 US US10/728,330 patent/US20040132741A1/en not_active Abandoned
- 2003-12-04 US US10/727,956 patent/US20040087595A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
LOWRY ET AL., J. BIOL. CHEM., vol. 193, 1951, pages 265 |
Cited By (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087750B2 (en) | 2000-10-20 | 2006-08-08 | Biovitrum Ab | Compounds, their use and preparation |
US7524839B2 (en) | 2000-10-20 | 2009-04-28 | Biovitrum Am (Publ.) | Compounds, their use and preparation |
US6790848B2 (en) | 2001-06-15 | 2004-09-14 | Syntex (U.S.A.) Llc | 4-piperazinylindole derivatives with 5-HT6 receptor affinity |
WO2002102774A1 (en) * | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
EP1408976A1 (en) * | 2001-07-20 | 2004-04-21 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
EP1408976A4 (en) * | 2001-07-20 | 2007-05-16 | Psychogenics Inc | Treatment for attention-deficit hyperactivity disorder |
WO2003068771A1 (en) * | 2002-02-18 | 2003-08-21 | Glaxo Group Limited | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors |
US7214674B2 (en) | 2002-02-18 | 2007-05-08 | Glaxo Group Limited | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors |
US7601837B2 (en) | 2002-03-27 | 2009-10-13 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US8236947B2 (en) | 2002-03-27 | 2012-08-07 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US7452888B2 (en) | 2002-03-27 | 2008-11-18 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
US7799774B2 (en) | 2002-03-27 | 2010-09-21 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US7977337B2 (en) | 2002-03-27 | 2011-07-12 | Glaxo Group Limited | Quinoline derivatives and their use as 5-HT6 ligands |
US6774241B2 (en) | 2002-06-05 | 2004-08-10 | Roche Palo Alto Llc | 1-sulfonyl-4-aminoalkoxy indole derivatives and uses thereof |
WO2003104193A1 (en) * | 2002-06-05 | 2003-12-18 | F. Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
WO2004026831A1 (en) * | 2002-09-17 | 2004-04-01 | F. Hoffmann-La Roche Ag | 2,4-substituted indoles and their use as 5-ht6 modulators |
CN1301970C (en) * | 2002-09-17 | 2007-02-28 | 弗·哈夫曼-拉罗切有限公司 | 2,4-substituted indoles and their use as 5-HT6 modulators |
US7381739B2 (en) | 2002-09-17 | 2008-06-03 | Roche Palo Alto Llc | 2,4-substituted indoles and methods of use |
CN100422171C (en) * | 2003-02-14 | 2008-10-01 | 惠氏公司 | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
US9775829B2 (en) | 2003-07-22 | 2017-10-03 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
WO2005037834A1 (en) * | 2003-10-20 | 2005-04-28 | Biovitrum Ab | NOVEL TETRAYDROSPIRO{PIPERIDINE-2,7’ -PYRROLO[3,2-b]PYRIDINE DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS |
JP2007509898A (en) | 2003-11-03 | 2007-04-19 | プロビオドルグ エージー | Useful combinations for the treatment of neurological disorders |
US7973069B2 (en) | 2004-07-14 | 2011-07-05 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7381728B2 (en) | 2004-07-28 | 2008-06-03 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
US7696229B2 (en) | 2006-02-17 | 2010-04-13 | Memory Pharmaceuticals Corporation | Compounds having 5-HT6 receptor affinity |
US7713978B2 (en) | 2006-03-31 | 2010-05-11 | Nigel Paul King | Compounds |
KR101103023B1 (en) * | 2007-01-08 | 2012-01-05 | 수벤 라이프 사이언시스 리미티드 | 5-heterocyclylalkyl-n-arylsulfonylindole compounds and their use as 5-ht6 ligands |
NO341713B1 (en) * | 2007-01-08 | 2018-01-08 | Suven Life Sciences Ltd | 5- (Heterocyclyl) alkyl-n- (arylsulfonyl) indole compounds and their use as 5-HT6 ligands |
EA017007B1 (en) * | 2007-01-08 | 2012-09-28 | Сувен Лайф Сайенсиз Лимитед | 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-htligands |
WO2008084492A1 (en) * | 2007-01-08 | 2008-07-17 | Suven Life Sciences Limited | 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands |
US8470830B2 (en) | 2007-01-08 | 2013-06-25 | Suven Life Sciences Limited | 5-(heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds and their use as 5-HT6 ligands |
US7750038B2 (en) | 2007-03-06 | 2010-07-06 | Wyeth Llc | Sulfonylated heterocycles useful for modulation of the progesterone receptor |
US8003670B2 (en) | 2007-05-03 | 2011-08-23 | Suven Life Sciences Limited | Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands |
US9808455B2 (en) | 2007-12-12 | 2017-11-07 | Axovant Sciences Gmbh | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US10787437B2 (en) | 2008-04-02 | 2020-09-29 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US10059691B2 (en) | 2008-04-02 | 2018-08-28 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
US8404720B2 (en) | 2008-09-17 | 2013-03-26 | Suven Life Sciences Limited | Aryl sulfonamide amine compounds and their use as 5-HT6 ligands |
US9745270B2 (en) | 2008-10-28 | 2017-08-29 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
TWI481605B (en) * | 2008-11-11 | 2015-04-21 | Wyeth Corp | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
WO2010056644A1 (en) * | 2008-11-11 | 2010-05-20 | Wyeth Llc | 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS |
KR101323417B1 (en) * | 2008-11-11 | 2013-10-29 | 와이어쓰 엘엘씨 | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
US8063053B2 (en) | 2008-11-11 | 2011-11-22 | Wyeth Llc | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands |
AP2814A (en) * | 2008-11-11 | 2013-12-31 | Wyeth Llc | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
EA018369B1 (en) * | 2008-11-11 | 2013-07-30 | УАЙТ ЭлЭлСи | 2-methyl-1-(phenylsulfonyl)-4-piperazin-1-yl-1h-benzimidazole, use thereof and composition comprising it |
AU2009314221B2 (en) * | 2008-11-11 | 2012-08-30 | Wyeth Llc | 1-(Arylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzimidazoles as 5-Hydroxytryptamine-6 Ligands |
US8940716B2 (en) | 2010-05-06 | 2015-01-27 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as GPR119 modulators |
US8293738B2 (en) | 2010-05-12 | 2012-10-23 | Abbott Laboratories | Indazole inhibitors of kinase |
WO2013001499A1 (en) | 2011-06-29 | 2013-01-03 | Adamed Sp. Z O.O. | Indoleamine derivatives for the treatment of central nervous system diseases |
WO2015019365A1 (en) | 2013-08-07 | 2015-02-12 | Cadila Healthcare Limited | N-cyanomethylamides as inhibitors of janus kinase |
US9556148B2 (en) | 2013-08-07 | 2017-01-31 | Cadila Healthcare Limited | N-cyanomethylamides as inhibitors of janus kinase |
US9663498B2 (en) | 2013-12-20 | 2017-05-30 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
US9550754B2 (en) | 2014-09-11 | 2017-01-24 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
WO2016038160A1 (en) * | 2014-09-11 | 2016-03-17 | AbbVie Deutschland GmbH & Co. KG | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy |
US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
US10034859B2 (en) | 2015-07-15 | 2018-07-31 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US11304932B2 (en) | 2015-07-15 | 2022-04-19 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
WO2020002611A1 (en) | 2018-06-28 | 2020-01-02 | Phenex-Fxr Gmbh | Novel lxr modulators with bicyclic core moiety |
US11618747B2 (en) | 2018-06-28 | 2023-04-04 | Orsobio, Inc. | LXR modulators with bicyclic core moiety |
US11970484B2 (en) | 2018-06-28 | 2024-04-30 | Orsobio, Inc. | LXR modulators with bicyclic core moiety |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2298738B1 (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | |
AU2002220051A1 (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | |
US7557098B2 (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | |
US6509357B1 (en) | 1-aryl or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
JP4323810B2 (en) | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
EP1592683A2 (en) | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | |
JP2004526781A (en) | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptoamine-6 ligands | |
US20090239863A1 (en) | 1-aryl-or 1- alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
AU2002307424A1 (en) | Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytrypltamine-6 ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2426031 Country of ref document: CA Ref document number: 155443 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001992697 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002220051 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/003800 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037006000 Country of ref document: KR Ref document number: 525592 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002539322 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037006000 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/04188 Country of ref document: ZA Ref document number: 200304188 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200300528 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018216587 Country of ref document: CN |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001992697 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 525592 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 525592 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002220051 Country of ref document: AU |